



ASX Announcement

4 December 2020

Lapse of Unlisted Share Options

Invion Limited (ASX:IVX) wishes to advise that the following unlisted share options have lapsed.

| Lapsed Options | Exercise Price | Expiry Date |
|----------------|----------------|-------------|
| 8,177,284 | \$0.0300 | 12/02/2023 |
| 5,000 | \$0.0175 | 18/11/2020 |

The number of options on hand following the lapse of the above options are as follows:

| *ASX security code and description | *Total number of +securities on issue |
|-------------------------------------|---------------------------------------|
| IVXAT OPT @ \$0.03 Exp 12/02/2023 | 199,434,880 |
| IVXAU OPT @ \$0.02 Exp 30/10/2023 | 2,725,761 |
| IVXAV OPT @ \$0.0172 Exp 31/08/2024 | 20,443,211 |
| IVXAAA OPT @ \$0.02 Exp 01/07/2024 | 15,928,570 |
| IVXAY OPT @ \$0.0177 Exp 22/10/2024 | 20,443,211 |
| IVXAW OPT @ \$0.00 Exp 31/10/2024 | 5,689,623 |
| IVXAZ OPT @ \$0.0106 Exp 31/10/2024 | 2,725,762 |

Investor enquiries

Thian Chew (Chairman & CEO)

T: +61 3 9692 7222

E: investor@inviongroup.com

Media enquires

Brendon Lau

T: +61 409 341 613

E: brendon@vantagepointpartners.com.au

**About Invion**

Invion is a life-science company that is leading the global research and development of Photosoft™ technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the Photosoft™ technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). This announcement was approved for release by the Board of Invion Limited. For further information please contact investor@inviongroup.com.

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.